Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-02-09FDA Approved: FINGOLIMOD — Supplemental Application (Quallent Pharmaceuticals Health LLC)
The FDA approved a supplemental application for fingolimod submitted by Quallent Pharmaceuticals Health LLC.
-
CLINICAL_TRIALS trial_result · 2021-02-08Clinical Trial Update: Safety Study of GNbAC1 in Multiple Sclerosis Patients [Phase 2]
Phase 2 safety study of GNbAC1 in patients with Multiple Sclerosis has been completed.
-
CLINICAL_TRIALS trial_result · 2021-02-02Clinical Trial Update: Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine. [Phase 4]
A Phase 4 clinical trial update evaluating short and long-term outcomes in people with multiple sclerosis treated with fampridine.
-
CLINICAL_TRIALS trial_result · 2021-02-02Clinical Trial Update: Comparison of Robot-Assisted Gait Training and Conventional Therapy in Multiple Sclerosis Patients [NA]
A completed clinical trial comparing robot-assisted gait training to conventional therapy in people with multiple sclerosis; results posted …
-
FDA approval · 2021-01-29FDA Approved: VUMERITY — Supplemental Application (Biogen Inc.)
FDA approved a supplemental application for Biogen's VUMERITY (diroximel fumarate). The approval updates the product's labeling to reflect t…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2021-01-29FDA Approved: TECFIDERA — Supplemental Application (Biogen Inc.)
FDA approved a supplemental application for TECFIDERA (dimethyl fumarate) submitted by Biogen Inc., resulting in changes to the drug's label…
-
FDA approval · 2021-01-29FDA Approved: PLEGRIDY PEN — Supplemental Application (Biogen Inc.)
The FDA approved Biogen's supplemental application for the PLEGRIDY PEN (peginterferon beta-1a), a pen-delivery device for administering peg…
-
FDA approval · 2021-01-23FDA Approved: MAYZENT — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for MAYZENT (siponimod) from Novartis Pharmaceuticals Corporation. The approval updates the prod…
-
CLINICAL_TRIALS trial_result · 2021-01-22Clinical Trial Update: Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS [Phase 4]
Phase 4 trial investigating ACTH effects on myelination in subjects with multiple sclerosis; study terminated with results posted.
-
FDA approval · 2021-01-15FDA Approved: BACLOFEN — Original Application (MAlA Pharmaceuticals, Inc.)
FDA approved the original application for baclofen, authorizing its marketing as a generic drug from MAlA Pharmaceuticals, Inc.
-
FDA approval · 2020-12-30FDA Approved: FINGOLIMOD — Original Application (Ascend Laboratories, LLC)
The FDA approved the original application for a generic fingolimod hydrochloride product from Ascend Laboratories, LLC, enabling a generic v…
-
FDA approval · 2020-12-18FDA Approved: FINGOLIMOD — Original Application (Apotex Corp.)
FDA approved Apotex Corp.'s original application for fingolimod (generic), enabling a generic version of the MS therapy.
-
FDA approval · 2020-12-15FDA Approved: TERIFLUNOMIDE — Supplemental Application (MSN LABORATORIES PRIVATE LIMITED)
FDA approved a supplemental application for teriflunomide filed by MSN Laboratories Private Limited.
-
FDA approval · 2020-12-14FDA Approved: OCREVUS — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Ocrevus (ocrelizumab) from Genentech, Inc. This action approves changes to the BLA submission fo…
-
CLINICAL_TRIALS trial_result · 2020-11-30Clinical Trial Update: Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis [Phase 3]
Phase 3 pediatric trial evaluating efficacy, safety, and pharmacokinetics of teriflunomide in children with relapsing forms of multiple scle…
-
CLINICAL_TRIALS trial_result · 2020-11-25Clinical Trial Update: Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS) [Phase 3]
Phase 3 study update for ozanimod (RPC1063) in relapsing multiple sclerosis completed with posted results.
-
CLINICAL_TRIALS trial_result · 2020-11-23Clinical Trial Update: Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) [Phase 3]
Phase 3 trial of MD1003 in progressive multiple sclerosis was terminated; results posted in 2020.
-
FDA approval · 2020-11-20FDA Tentative Approval: BETASERON — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
The FDA issued tentative approval for Bayer's supplemental application for BETASERON (interferon beta-1b), indicating the product meets regu…
-
FDA approval · 2020-11-09FDA Approved: GLATOPA — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for GLATOPA (glatiramer acetate) submitted by Sandoz Inc.
-
FDA approval · 2020-11-09FDA Approved: GLATOPA — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for GLATOPA (glatiramer acetate) from Sandoz Inc., making it an approved generic treatment for relap…
-
FDA approval · 2020-11-06FDA Approved: AUBAGIO — Supplemental Application (Genzyme Corporation)
FDA approved a supplemental application for AUBAGIO (teriflunomide) by Genzyme Corporation.
-
FDA approval · 2020-11-06FDA Approved: OCREVUS — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Ocrevus (ocrelizumab) from Genentech, Inc.
-
FDA approval · 2020-11-03FDA Approved: BACLOFEN — Supplemental Application (Northstar RxLLC)
The FDA approved a supplemental application for baclofen from Northstar RxLLC, finalizing changes to an approved generic product.
-
FDA label_change · 2020-10-29FDA Approved: BACLOFEN — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for baclofen submitted by Chartwell RX, LLC.
-
FDA approval · 2020-10-28FDA Approved: FINGOLIMOD HYDROCHLORIDE — Original Application (Accord Healthcare Inc.)
FDA approved fingolimod hydrochloride as an Original Application generic product (ANDA 207991) from Accord Healthcare Inc. for the treatment…